With 0.51 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.77 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $18.56 whereas the lowest price it dropped to was $17.58. The 52-week range on GRAL shows that it touched its highest point at $24.92 and its lowest point at $12.33 during that stretch. It currently has a 1-year price target of $16.00.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GRAL was down-trending over the past week, with a drop of -4.73%, but this was down by -4.32% over a month. Three-month performance surged to 35.25% while six-month performance rose 15.69%.
Float and Shares Shorts:
At present, 33.20 million GRAL shares are outstanding with a float of 28.81 million shares on hand for trading. On 2024-12-13, short shares totaled 4.9 million, which was 1457.0 higher than short shares on 1731628800. In addition to Mr. Robert P. Ragusa as the firm’s CEO & Director, Dr. Joshua J. Ofman M.D., M.S.H.S serves as its President.
Institutional Ownership:
Through their ownership of 0.67061996 of GRAL’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, GRAL reported revenue of $28652000.0 and operating income of -$183507000.0. The EBITDA in the recently reported quarter was -$144277000.0 and diluted EPS was -$3.94.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With GRAL analysts setting a high price target of 16.0 and a low target of 16.0, the average target price over the next 12 months is 16.0. Based on these targets, GRAL could drop -10.71% to reach the target high and fall by -10.71% to reach the target low. Reaching the average price target will result in a decline of -10.71% from current levels.
Analysts have provided yearly estimates in a range of -$64.02209 being high and -$66.03055 being low. For GRAL, this leads to a yearly average estimate of -$65.16.
